Aethlon Medical (NASDAQ: AEMD) trims Q1 costs and adds $4M cash
Rhea-AI Filing Summary
Aethlon Medical, Inc. reported fiscal first-quarter 2027 results for the quarter ended June 30, 2026 and provided an update on its Hemopurifier program. Clinically, the company dosed the first participant in the third and final cohort of its Phase 1 oncology study in Australia. Early observations from the first two cohorts showed consistent decreases in tumor-derived extracellular vesicles and cancer‑linked microRNAs and signs of immune changes; these findings are preliminary and will be fully evaluated after study completion. A Long COVID manuscript describing extracellular vesicles in patients was accepted for publication, showing that these vesicles bind to the Hemopurifier’s GNA affinity resin.
Cash and cash equivalents were approximately $4.9 million as of June 30, 2026. Subsequent to quarter‑end, the company raised about $4.0 million in gross proceeds via a public offering and believes its cash resources can fund operations for at least the next 12 months. Consolidated operating expenses decreased 11.9% to about $1.6 million from $1.8 million in the prior‑year quarter, and operating loss narrowed accordingly. Net loss attributable to common stockholders was $1.55 million, or $4.02 per share, compared with $1.76 million, or $42.42 per share, a year earlier.
Positive
- Operating expenses fell 11.9% to approximately $1.6 million from $1.8 million in the prior‑year quarter, narrowing operating loss and demonstrating tighter cost control.
- The company completed a $4.0 million public equity financing post‑quarter and states it believes its cash can fund operations for at least the next 12 months.
Negative
- None.
Filing Explained
The balance sheet reports
8-K Event Classification
Key Figures
Key Terms
Breakthrough Device Designation regulatory
extracellular vesicles medical
operating loss financial
additional paid-in capital financial
affinity resin technical
Earnings Snapshot
FAQ
What were Aethlon Medical (AEMD)'s operating expenses in Q1 fiscal 2027?
What net loss did Aethlon Medical (AEMD) report for Q1 fiscal 2027?
How much cash does Aethlon Medical (AEMD) have and what is its runway?
What financing did Aethlon Medical (AEMD) complete after Q1 fiscal 2027?
What clinical progress did Aethlon Medical (AEMD) report for its Hemopurifier program?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
|
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
|
|
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including
area code: (
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
|
|
The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
The information provided below in “Item 7.01 - Regulation FD Disclosure” of this Current Report on Form 8-K (this “Current Report”) is incorporated by reference into this Item 2.02.
Item 7.01 Regulation FD Disclosure.
On August 13, 2026, Aethlon Medical, Inc. (the “Company”) issued a press release regarding its financial results for the quarter ended June 30, 2026. A copy of that press release is furnished as Exhibit 99.1 hereto and incorporated herein by reference.
The information set forth under Item 7.01 of this Current Report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section. The information in Item 7.01 of this Current Report, including Exhibit 99.1, shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language in any such filing, except as expressly set forth by specific reference in such a filing. This Current Report will not be deemed an admission as to the materiality of any information in this Current Report that is required to be disclosed solely by Regulation FD.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit Number | Description | |
| 99.1 | Press Release, dated August 13, 2026 | |
| 104 | Cover Page Interactive Data File (embedded within the inline XBRL Document) |
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: August 13, 2026 | AETHLON MEDICAL, INC. | |
| By: | /s/ James B. Frakes | |
|
Name: Title: |
James B. Frakes Chief Executive Officer and Chief Financial Officer | |
| 3 |
Exhibit 99.1
Aethlon Medical Reports Q1 Fiscal 2027 Results and Progress on Hemopurifier® Program
Conference Call Today at 4:30 p.m. ET
SAN DIEGO, August 13, 2026 -- Aethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a clinical-stage medical therapeutic company, today announced financial results for fiscal first quarter ended June 30, 2026, and provided a corporate update.
“We advanced our clinical and research programs during the quarter,” said James Frakes, CEO and CFO. “We treated the first participant in the third and final dosing cohort of our Phase 1 oncology study in Australia, and early biomarker signals from the initial cohorts support continuing evaluation of the Hemopurifier. We also had a Long COVID manuscript accepted for publication, which strengthens the scientific case for studying extracellular vesicles in post-viral conditions.”
Clinical highlights
| · | Phase 1 oncology study: First participant dosed in the third and final cohort in Australia. Early observations from the first two cohorts showed consistent decreases in tumor-derived extracellular vesicles and microRNAs linked to cancer progression and improvements in immune fumction associated with potential response to immunotherapy. These observations are preliminary and will be evaluated fully after study completion. | |
| · | Long COVID publication: A manuscript describing extracellular vesicle characteristics in patients with Long COVID was accepted for publication in the International Journal of Molecular Sciences. The manuscript demonstrates that the extracellular vesicles isolated from the plasma of individuals with Long COVID bind to the proprietary GNA affinity resin in the Hemopurifier. |
Financial highlights
| · | Cash and liquidity: Cash and cash equivalents were approximately $4.9 million as of June 30, 2026. | |
| · | Post-quarter financing: Subsequent to quarter-end, Aethlon raised approximately $4.0 million in gross proceeds through a public offering of common stock. Based on current plans, the company believes its cash resources are sufficient to fund operations for at least the next 12 months. | |
| · | Operating expenses: Consolidated operating expenses for the quarter decreased 11.9% to approximately $1.6 million versus $1.8 million in the prior-year quarter, driven by lower professional fees and reduced general and administrative and preclinical research costs. Operating loss declined accordingly. |
The consolidated balance sheets for June 30, 2026, and March 31, 2026 and the consolidated statements of operations for the fiscal quarters ended June 30, 2026, and 2025, are included at the end of this release.
| 1 |
Conference Call
Management will host a conference call today, Thursday, August 13, 2026, at 4:30 p.m. ET to review the Company’s financial results and recent corporate developments. Following management’s formal remarks, there will be a question-and-answer session.
Interested parties can register for the conference call by navigating to https://dpregister.com/sreg/10211144/104a3acc428. Please note that registered participants will receive their dial-in number upon registration.
Interested parties without internet access or unable to pre-register may dial in by calling:
PARTICIPANT DIAL IN (TOLL FREE): 1-844-836-8741
PARTICIPANT INTERNATIONAL DIAL IN: 1-412-317-5442
All callers should ask for the Aethlon Medical, Inc. conference call.
A replay of the call will be available approximately one hour after the end of the call through September 13, 2026. The replay can be accessed via Aethlon Medical’s website or by dialing 1-855-669-9658 (USA or Canada) or 1-412-317-0088 (international) or Canada toll free at 1-855-669-9658. The replay conference ID number is 6711524.
About the Hemopurifier®
The Aethlon Hemopurifier is an investigational medical device designed to remove enveloped viruses and tumor-derived extracellular vesicles (EVs) from circulation. It is used extracorporeally with a blood pump and combines plasma separation, size exclusion, and affinity binding using a plant lectin resin that targets mannose-rich surfaces found on EVs and viruses. EVs released by solid tumors are believed to play a role in metastasis and the resistance to immunotherapies and chemotherapy. Removal of enveloped viruses and extracellular vesicles has been demonstrated in both in vitro studies and human subjects.
The Hemopurifier holds a U.S. Food and Drug Administration Breakthrough Device Designation for:
The treatment of individuals with advanced or metastatic cancer unresponsive to or intolerant of standard-of-care therapy; and the treatment of life-threatening viruses not addressed with approved therapies.
About Aethlon Medical, Inc.
Aethlon Medical, Inc. (Nasdaq: AEMD) is a clinical-stage medical therapeutic company headquartered in San Diego, California. The Company is advancing the Hemopurifier®, an investigational extracorporeal immunotherapeutic platform designed to remove tumor-derived extracellular vesicles and enveloped viruses from circulation for potential applications in oncology, infectious disease, and other disease states.
For more information, visit www.AethlonMedical.com and follow the Company on LinkedIn.
| 2 |
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Forward-looking statements in this release include, among others, statements regarding: the investigational status and potential safety, feasibility, or utility of the Hemopurifier®; the Company’s ability to initiate, enroll, conduct, and complete its clinical trials, including in Australia; the timing, scope, design, and potential outcomes or interpretation of such studies; the Company’s ability to manufacture the Hemopurifier in sufficient quantities for clinical and potential future commercial use; the availability and adequacy of capital to support ongoing operations; statements regarding the Company’s Ebola-related compassionate use activities and any resulting interest from public health organizations; the Company’s collaborative research activities, including rheumatoid arthritis, chronic kidney disease, and other extracellular vesicle- associated conditions; and the Company’s ability to advance or expand its research programs in oncology, infectious diseases, and other conditions associated with extracellular vesicles. Such forward-looking statements are subject to significant risks and uncertainties, and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such differences include, without limitation, the fact that the cash on hand may not be sufficient to support operations for the next 12 months without additional financing, the Company's ability to raise additional capital on terms favorable to the Company, or at all; the Company’s ability to successfully complete development of the Hemopurifier; the Company’s ability to successfully demonstrate the utility and safety of the Hemopurifier in cancer and infectious diseases and in the transplant setting; the Company’s ability to achieve and realize the anticipated benefits from operational and financial milestones; the Company’s ability to maintain its Nasdaq listing, the Company’s ability to obtain approval from the Ethics Committee of its third location in Australia, including on the timeline expected by the Company; the Company’s ability to enroll additional patients in its oncology clinical trial in Australia, including on the timeline expected by the Company; the Company’s ability to manage and successfully complete its clinical trials; the Company’s ability to successfully manufacture the Hemopurifier in sufficient quantities for its clinical trials; unforeseen changes in regulatory requirements; the Company’s collaborative research with UCSF Long Covid Clinic; and the Company’s ability to further research potential applications of the Hemopurifier in other EV-associated diseases and other potential risks. The foregoing list of risks and uncertainties is illustrative but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2026, and in the Company's other filings with the Securities and Exchange Commission, including its Quarterly Reports on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances. Because the Hemopurifier® is an investigational device, its safety and effectiveness have not been established, and no conclusions should be drawn regarding clinical benefit. The observations contained in this release are from an early feasibility study and should not be interpreted as evidence of clinical benefit or safety beyond the study parameters.
Company
Contact:
Jim Frakes
Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com
Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com
| 3 |
AETHLON MEDICAL, INC. AND SUBSIDIARY
Condensed Consolidated Balance Sheets
| June 30, 2026 | ||||||||
| (Unaudited) | March 31, 2026 | |||||||
| ASSETS | ||||||||
| CURRENT ASSETS | ||||||||
| Cash and cash equivalents | $ | 4,933,579 | $ | 5,026,458 | ||||
| Deferred offering costs | 394,192 | 210,985 | ||||||
| Prepaid expenses and other current assets | 283,143 | 332,094 | ||||||
| TOTAL CURRENT ASSETS | 5,610,914 | 5,569,537 | ||||||
| Property and equipment, net | 293,112 | 356,822 | ||||||
| Operating lease right-of-use asset, net | 232,195 | 307,820 | ||||||
| Restricted cash | 99,150 | 98,928 | ||||||
| TOTAL ASSETS | $ | 6,235,371 | $ | 6,333,107 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| CURRENT LIABILITIES | ||||||||
| Accounts payable | $ | 411,373 | $ | 384,550 | ||||
| Due to related parties | 68,250 | 68,250 | ||||||
| Operating lease liability, current portion | 255,052 | 336,718 | ||||||
| Other current liabilities | 301,367 | 657,317 | ||||||
| TOTAL LIABILITIES, ALL CURRENT | 1,036,042 | 1,446,835 | ||||||
| STOCKHOLDERS' EQUITY | ||||||||
| Common stock, $0.001 par value; 20,000,000 shares authorized as of June 30, 2026 and March 31, 2026; 477,402 shares issued and outstanding as of June 30, 2026 and 314,100 shares issued and outstanding at March 31, 2026 | 477 | 314 | ||||||
| Additional paid-in capital | 181,891,939 | 180,024,947 | ||||||
| Accumulated other comprehensive loss | (38,889 | ) | (32,703 | ) | ||||
| Accumulated deficit | (176,654,198 | ) | (175,106,286 | ) | ||||
| TOTAL STOCKHOLDERS' EQUITY | 5,199,329 | 4,886,272 | ||||||
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ | 6,235,371 | $ | 6,333,107 | ||||
| 4 |
AETHLON MEDICAL, INC. AND SUBSIDIARY
Condensed Consolidated Statements of Operations and Comprehensive Loss
For the three months ended June 30, 2026 and 2025
(Unaudited)
| Three Months | Three Months | |||||||
| Ended | Ended | |||||||
| June 30, 2026 | June 30, 2025 | |||||||
| OPERATING EXPENSES | ||||||||
| Professional fees | $ | 333,569 | $ | 476,032 | ||||
| Payroll and related expenses | 583,183 | 581,000 | ||||||
| General and administrative | 662,450 | 735,358 | ||||||
| Total operating expenses | 1,579,202 | 1,792,390 | ||||||
| OPERATING LOSS | (1,579,202 | ) | (1,792,390 | ) | ||||
| Interest income, net | 31,290 | 30,532 | ||||||
| NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS | (1,547,912 | ) | (1,761,858 | ) | ||||
| OTHER COMPREHENSIVE LOSS | (6,186 | ) | (5,244 | ) | ||||
| COMPREHENSIVE LOSS | $ | (1,554,098 | ) | $ | (1,767,102 | ) | ||
| Basic and diluted net loss per share attributable to common stockholders | $ | (4.02 | ) | $ | (42.42 | ) | ||
| Weighted average number of common shares outstanding - basic and diluted | 384,705 | 41,529 | ||||||
| 5 |